PROFOUND MEDICAL CORP. (PROF) Spending and interest coverage
- R&D / revenue · 12 months: Value 105.15%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 25.37%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 105.15% | Research and development expense / revenue. Period ending 2026-06-30. $20.61M ÷ $19.60M × 100 ≈ 105.15% |
| Stock-based compensation / revenue · 12 months | 25.37% | Share-based compensation / revenue. Period ending 2026-06-30. $4.97M ÷ $19.60M × 100 ≈ 25.37% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 20.61M USD | Research and Development Expense |
| Revenue | 19.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.97M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -35.37M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.61M | $19.60M | $4.97M | $-35.37M | (m) | 105.15% | 25.37% | (m) | (m) |
| 2026-03-31 | $21.05M | $19.09M | $5.55M | $-38.11M | (m) | 110.24% | 29.06% | (m) | (m) |
| 2025-12-31 | $20.60M | $16.10M | $5.49M | $-41.25M | (m) | 127.94% | 34.10% | (m) | (m) |
| 2025-09-30 | $20.97M | $13.41M | $4.55M | $-42.23M | (m) | 156.43% | 33.94% | (m) | (m) |
| 2025-06-30 | $19.72M | $10.89M | $3.49M | $-42.31M | (m) | 181.09% | 32.01% | (m) | (m) |
| 2025-03-31 | $17.83M | $10.86M | $2.80M | $-36.35M | (m) | 164.13% | 25.81% | (m) | (m) |
| 2024-12-31 | $16.96M | $9.74M | $2.58M | $-33.06M | (m) | 174.18% | 26.50% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $14.42M | $5.90M | $3.42M | $-28.65M | (m) | 244.52% | 57.93% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |